Revolutionizing Lung Cancer Detection: LumenGuides Introduces Naviscope

The world's first autonomous, radiation-free bronchoscopy system powered by AI and fiber optic sensors

Breaking Through Traditional Limitations

Early-stage lung cancer detection has long been hampered by the limitations of traditional bronchoscopy systems. Current methods rely heavily on radiation exposure, external imaging, and operator expertise — creating barriers to accessible, accurate diagnosis. LumenGuides is changing this paradigm entirely.

Our breakthrough innovation, Naviscope, represents the world's first single-use, radiation-free, AI-powered bronchoscopy system. By combining advanced fiber optic sensors (FBGs) with cutting-edge AI architectures, Naviscope can autonomously reach peripheral lung lesions that were previously inaccessible using standard bronchoscopes or even robotic systems.

2025: A Year of Remarkable Milestones

Massive Market Opportunity

The global bronchoscopy market represents an enormous opportunity, with projections showing growth to $17 billion by 2030. This growth is driven by several critical factors:

Funding the Future: $4M Seed Round

LumenGuides is currently raising a $4M Seed Round to accelerate our path to market and clinical validation. These funds will enable us to:

• Final design freeze + Verification & Validation (V&V)
• Completion of pre-clinical animal studies
• Clinical pilot program: 30 patients across 3+ hospitals
• FDA regulatory pathway (510(k), predicate K242070)

World-Class Clinical Collaborators

We're honored to work alongside leading medical professionals who share our vision for transforming lung cancer detection:

Leading the Innovation

At the helm of this revolutionary technology is Limor Prigan, ChE, MBA, Founder & CEO of LumenGuides. With her unique combination of chemical engineering expertise and business acumen, Limor is driving the company's mission to reshape the future of lung biopsies.